Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 558

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 558
---
 continue to evaluate the effect on the tax provision each reporting period. Results of Operations Comparison of the Three and Nine Months Ended September 30, 2024 and 2023 Revenue

| ​                          
 ​                          
 ​                          | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months EndedSeptember 30, 
 2024                            
 Dollar amounts in thousands     |   |       |   | ​ | ​ | 2023 |   |       |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 Dollar amounts in thousands    |   |       |   | ​ | ​ | 2023 |   |        |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ 
 ​ |
|:---------------------------|:--|:--|:--------------------------------|:--|------:|:--|:--|:--|:-----|:--|------:|:--|:--|:--|:---------|:--|:--|:-------------------------------|:--|------:|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:---------|:--|
| Collaborative revenue      | ​ | ​ | ​                               | $ | 1,298 | ​ | ​ | ​ | ​    | $ | 2,471 | ​ | ​ | ​ | -47%     | ​ | ​ | ​                              | $ | 2,086 | ​ | ​ | ​ | ​    | $ | 10,631 | ​ | ​ | ​ | -80%     | ​ |
| Commercial supply revenue  | ​ | ​ | ​                               | ​ |     — | ​ | ​ | ​ | ​    | ​ | 1,252 | ​ | ​ | ​ | -100%    | ​ | ​ | ​                              | ​ |   640 | ​ | ​ | ​ | ​    | ​ |  5,843 | ​ | ​ | ​ | -89%     | ​ |
| License and milestone fees | ​ | ​ | ​                               | ​ |     — | ​ | ​ | ​ | ​    | ​ |   910 | ​ | ​ | ​ | -100%    |